Mega Genomics Limited (Stock code: 6667) has announced that it has met all resumption guidance set by The Stock Exchange of Hong Kong Limited, paving the way for trading in its shares to resume on 27 February 2026. This follows the company’s completion of an independent forensic investigation, an internal control review, and the publication of all outstanding financial results.

The announcement explains that the delay in financial disclosures for the year ended 31 December 2024 arose from audit concerns about revenue recognition for genetic testing kits and promotional expenses. An independent professional firm completed a forensic investigation, while an external adviser carried out an internal control review. Both concluded that the company’s measures addressed the main issues, including updates to revenue recognition procedures, stricter contract management, and enhanced monitoring of promotion activities. The current auditor has issued an unqualified opinion on Mega Genomics’ 2024 consolidated financial statements.

According to the latest disclosures, revenue for the financial year ended 31 December 2024 increased 8.50% year on year to RMB164.20 million. Net profit reached RMB45.00 million, surging from RMB30.00 million in 2023, indicating stronger profitability and improved margins. For the six months ended 30 June 2025, Mega Genomics recorded revenue of RMB81.30 million and a net profit of RMB27.30 million. Management noted that the scale and proportion of its genetic kits business has gradually declined, with resources shifting back toward on-site blood collection testing and packages.

Following the confirmations of regulatory compliance, the company has reaffirmed its sufficient level of operations, adequate assets, and effective corporate governance. The total assets of Mega Genomics as of 31 December 2024 were RMB738.50 million, with net assets of RMB614.70 million. The company’s disclosures highlight stable operations, ongoing research and development activities, and a diversified range of genetic testing offerings.

Mega Genomics states that all necessary remedial actions have been completed, with the Stock Exchange’s resumption conditions fulfilled. Trading in the company’s shares is set to resume at 9:00 a.m. on 27 February 2026.